CSF proteomic signature predicts progression to Alzheimer's disease dementia

Eleonora M Vromen*, Marta Del Campo Milán, Philip Scheltens, Charlotte E Teunissen, Pieter Jelle Visser, Betty M Tijms

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction: Individuals in the Alzheimer's disease (AD) continuum with mild cognitive impairment (prodromal AD) are at increased risk to develop dementia. Still, underlying pathophysiological processes remain unclear. We studied whether cerebrospinal fluid (CSF) proteome changes are related to time to clinical progression in prodromal AD.

Methods: We measured 671 CSF proteins in 49 prodromal AD individuals (67±7 years old, 22 [45%] female) from the Amsterdam Dementia Cohort. Associations of protein levels with time to dementia onset were tested with Cox regression models, followed by biological pathway enrichment analysis.

Results: Eighteen (36%) individuals developed dementia during follow-up. In total, 128 (98%) proteins were associated with a 1.4- to 17-fold increased risk of progression to dementia (all P < .05). These proteins showed enrichment for immune system processes, signal transduction, neuronal death, and neurodevelopmental biology.

Discussion: CSF proteome changes related to rate of progression to dementia can be detected in prodromal AD, providing more insight into processes involved in early AD pathophysiology.

Original languageEnglish
Article numbere12240
Number of pages5
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume8
Issue number1
DOIs
Publication statusPublished - 2022

Keywords

  • ASSOCIATION WORKGROUPS
  • Alzheimer's disease
  • CEREBROSPINAL-FLUID BIOMARKERS
  • DIAGNOSTIC GUIDELINES
  • MILD COGNITIVE IMPAIRMENT
  • NATIONAL INSTITUTE
  • RECOMMENDATIONS
  • cerebrospinal fluid
  • mild cognitive impairment
  • prognosis
  • proteomics

Cite this